Articles published by PaxMedica, Inc.
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
May 15, 2024
From PaxMedica, Inc.
Via GlobeNewswire
Tickers
PXMD
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
April 23, 2024
From PaxMedica, Inc.
Via GlobeNewswire
Tickers
PXMD
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
March 13, 2024
From PaxMedica, Inc.
Via GlobeNewswire
Tickers
PXMD
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
November 02, 2023
From PaxMedica, Inc.
Via GlobeNewswire
Tickers
PXMD
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
October 31, 2023
From PaxMedica, Inc.
Via GlobeNewswire
Tickers
PXMD
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
PaxMedica Announces 1-for-17 Reverse Stock Split
October 30, 2023
From PaxMedica, Inc.
Via GlobeNewswire
Tickers
PXMD
![](https://ml.globenewswire.com/media/f1db55df-0c05-4ef5-a59d-7fe4419a4c9d/small/paxmedica-logo-jpg.jpg)
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
October 26, 2023
From PaxMedica, Inc.
Via GlobeNewswire
Tickers
PXMD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.